Autres langues Bausch + Lomb Corporation

Actions

BLCO

CA0717051076

Marché Fermé - Nyse Autres places de cotation 22:00:02 02/05/2024			Varia. 5j.	Varia. 1 janv.
13,86 ^USD	+0,87 %		-6,10 %	-18,76 %

02/05	RBC Capital revoit les résultats de Bausch + Lomb pour le 1er trimestre	MT
02/05	BAUSCH + LOMB CORPORATION : Deutsche Bank Securities confirme sa recommandation neutre	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Bausch Health Announces First Quarter 2024 Results	12:59
RBC Capital Reviews Bausch + Lomb's Q1 Results	02/05
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year	01/05
Bausch + Lomb Q1 Loss Widens, Revenue Increases	01/05
Bausch + Lomb Q1 Net Loss Widens, But Revenue Higher; Raises 2024 Revenue Growth Guidance	01/05
Bausch + Lomb: Q1 Earnings Snapshot	01/05
Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance	01/05
Bausch + Lomb Brief: Q1 Adjusted EBITDA (non-GAAP) of US$180 Million	01/05
Bausch + Lomb Brief: Q1 Revenue of US$1.099 Billion; GAAP Net Loss Attributable of $167 Million	01/05
Bausch + Lomb Announces First-Quarter 2024 Results	01/05
Bausch + Lomb Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	01/05
Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting	29/04
Bausch + Lomb Says Study Shows Improvements in Dry Eyes With Nutritional Supplement	25/04
Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes	25/04
Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	25/04
Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	25/04
Bausch + Lomb Corporation Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	25/04
RBC Previews Bausch Health's Q1, Trims Target to US$11	23/04
RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1	22/04
Bausch + Lomb Q1 Results Likely to be Impacted by Foreign Exchange Headwinds, RBC Says	22/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Bausch + Lomb Corporation

Actions

BLCO

CA0717051076

Autres langues

Filtres